Pediatric demyelinating disease and anti‐MOG antibody
SN Tenembaum - Clinical and Experimental Neuroimmunology, 2021 - Wiley Online Library
Significant progress has been made in the field of pediatric neuroimmunology over the past
few years. With the detection of conformationally correct myelin oligodendrocyte …
few years. With the detection of conformationally correct myelin oligodendrocyte …
Emerging targeted therapies for neuromyelitis optica spectrum disorders
C Valencia-Sanchez, DM Wingerchuk - BioDrugs, 2021 - Springer
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune, inflammatory disorder
of the central nervous system that typically presents with recurrent episodes of optic neuritis …
of the central nervous system that typically presents with recurrent episodes of optic neuritis …
Treatment of myelin oligodendrocyte glycoprotein immunoglobulin G–associated disease
S Healy, KT Elhadd, E Gibbons… - Clinical and …, 2021 - Wiley Online Library
Myelin oligodendrocyte glycoprotein (MOG) immunoglobulin G (IgG)–associated disease
(MOGAD) is increasingly recognized as a distinct nosological entity from aquaporin‐4 …
(MOGAD) is increasingly recognized as a distinct nosological entity from aquaporin‐4 …
A comparison of the effects of rituximab versus other immunotherapies for MOG-IgG-associated central nervous system demyelination: a meta-analysis
P Bai, M Zhang, J Yuan, R Zhu, N Li - Multiple Sclerosis and Related …, 2021 - Elsevier
Background Myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOG-AD) is now
recognised as a nosological entity with specific clinical and paraclinical features to aid early …
recognised as a nosological entity with specific clinical and paraclinical features to aid early …
Global trends in research on MOG antibody-associated disease: bibliometrics and visualization analysis
S Zheng, Y Wang, J Geng, X Liu, L Huo - Frontiers in Immunology, 2024 - frontiersin.org
Objective The purpose of this study was to investigate the current research status, focus
areas, and developmental trends in the field of Myelin oligodendrocyte glycoprotein …
areas, and developmental trends in the field of Myelin oligodendrocyte glycoprotein …
Myelin Oligodendrocyte Glycoprotein-Antibody Associated Disease: An Updated Review of the Clinical Spectrum, Pathogenetic Mechanisms and Therapeutic …
Clinical syndromes associated with antibodies against myelin oligodendrocyte glycoprotein
(MOG) are now recognized as a distinct neurological disease entity, and are gaining …
(MOG) are now recognized as a distinct neurological disease entity, and are gaining …
Differential efficacy of mycophenolate mofetil in adults with relapsing myelin oligodendrocyte glycoprotein antibody-associated disorders
M Wang, P Zeng, C Du, H Xue, Z Cui, H Zhang… - Multiple Sclerosis and …, 2021 - Elsevier
Background Myelin oligodendrocyte glycoprotein-immunoglobulin (MOG-IgG) associated
disorder (MOGAD) has been recognized as a distinct disease entity with recurrent attacks …
disorder (MOGAD) has been recognized as a distinct disease entity with recurrent attacks …
Optic neuritis in the era of NMOSD and MOGAD: a survey of practice patterns in Singapore
R Foo, C Yau, S Singhal, S Tow, JL Loo… - The Asia-Pacific …, 2022 - journals.lww.com
Purpose: The Optic Neuritis Treatment Trial was a landmark study with implications
worldwide. In the advent of antibody testing for neuromyelitis optica spectrum disease …
worldwide. In the advent of antibody testing for neuromyelitis optica spectrum disease …
Clinical profile and treatment outcome in MOGAD: a single-center case-series study in Guiyang, China
X Lei, S Guo, S Cui, Y Pu, A Zhang, D He - Frontiers in Neurology, 2022 - frontiersin.org
Background The clinical spectrum of myelin oligodendrocyte glycoprotein antibody-
associated disease (MOGAD) is expanding over time. However, the long-term management …
associated disease (MOGAD) is expanding over time. However, the long-term management …
[HTML][HTML] Clinical and radiographic features of a cohort of adult and pediatric subjects in the Pacific Northwest with myelin oligodendrocyte glycoprotein antibody …
K Martin, P Srikanth, A Kanwar, J Falardeau… - Multiple sclerosis and …, 2024 - Elsevier
Background Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is
a newly described clinical entity comprised of isolated or recurrent attacks of optic neuritis …
a newly described clinical entity comprised of isolated or recurrent attacks of optic neuritis …